Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

RMC-9805

🥰Excellent
Catalog No. T78212Cas No. 2922732-54-3
Alias Zoldonrasib, KRAS G12D inhibitor 18, KRAS G12D IN 18

RMC-9805 is a novel, mutant-selective, covalent and oral KRASG12D (ON) inhibitor. A stable and high affinity triple complex is formed between RMC-9805, KRASG12D, and cyclophilin A, which inhibits signal transduction downstream of KRASG12D (ON) by disrupting its interaction with downstream effectors. RMC-9805 can induce cell apoptosis and promote tumor regression in preclinical KRASG12D tumor models. With rich experience in compound synthesis, we can provide fast customized synthesis services for this product according to your research needs.

RMC-9805

RMC-9805

🥰Excellent
Purity: 99.27%
Catalog No. T78212Alias Zoldonrasib, KRAS G12D inhibitor 18, KRAS G12D IN 18Cas No. 2922732-54-3
RMC-9805 is a novel, mutant-selective, covalent and oral KRASG12D (ON) inhibitor. A stable and high affinity triple complex is formed between RMC-9805, KRASG12D, and cyclophilin A, which inhibits signal transduction downstream of KRASG12D (ON) by disrupting its interaction with downstream effectors. RMC-9805 can induce cell apoptosis and promote tumor regression in preclinical KRASG12D tumor models. With rich experience in compound synthesis, we can provide fast customized synthesis services for this product according to your research needs.
Pack SizePriceAvailabilityQuantity
1 mg$132 In Stock
5 mg$328 In Stock
10 mg$562 In Stock
25 mg$1,280 In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "RMC-9805"

Select Batch
Purity:99.27%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
RMC-9805 is a novel, mutant-selective, covalent and oral KRASG12D (ON) inhibitor. A stable and high affinity triple complex is formed between RMC-9805, KRASG12D, and cyclophilin A, which inhibits signal transduction downstream of KRASG12D (ON) by disrupting its interaction with downstream effectors. RMC-9805 can induce cell apoptosis and promote tumor regression in preclinical KRASG12D tumor models. With rich experience in compound synthesis, we can provide fast customized synthesis services for this product according to your research needs.
In vitro
METHODS: eCT26 (KRASG12D/G12D) and KPCY 6499c4 (KRASG12D/+) cells were treated with RMC-9805 (100 nM) for 48 hours, and cytokine levels were measured using a cytokine array. Cell surface expression was detected by flow cytometry.
RESULTS: CXCL1 and GM-CSF were reduced in eCT26 (KRASG12D/G12D) and KPCY 6499c4 (KRASG12D/+) cells, while PD-L1 and PVR were reduced; CXCL10 and CCL17 increased, while MHC-I and MHC-II increased. [2]
In vivo
METHODS: To detect in vivo anti-tumor activity, RMC-9805 (100 mg/kg) was orally administered to eCT26 (KRASG12D/G12D) xenograft tumor mice once a day for 4-8 days.
RESULTS: RMC-9805 exhibits anti-tumor activity in the KRAS G12D xenograft model. [2]
AliasZoldonrasib, KRAS G12D inhibitor 18, KRAS G12D IN 18
Chemical Properties
Molecular Weight1168.44
FormulaC63H88F3N11O7
Cas No.2922732-54-3
SmilesC(C(F)(F)F)N1C(=C2C=3C1=CC=C(C3)N4C[C@](C[C@H](NC([C@@H](N5C[C@@]6(CC5)CN(C(=O)[C@H]7[C@H](N7C)[C@@H]8CC8)CC6)[C@H]9CCCC9)=O)C(=O)N%10N[C@](C(=O)OCC(C)(C)C2)(CCC%10)[H])(OCC4)[H])C%11=C([C@@H](OC)C)N=CC(=C%11)N%12CCN(CC%12)C%13CC%13
Storage & Solubility Information
Storagekeep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 100 mg/mL (85.58 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM0.8558 mL4.2792 mL8.5584 mL42.7921 mL
5 mM0.1712 mL0.8558 mL1.7117 mL8.5584 mL
10 mM0.0856 mL0.4279 mL0.8558 mL4.2792 mL
20 mM0.0428 mL0.2140 mL0.4279 mL2.1396 mL
50 mM0.0171 mL0.0856 mL0.1712 mL0.8558 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy RMC-9805 | purchase RMC-9805 | RMC-9805 cost | order RMC-9805 | RMC-9805 chemical structure | RMC-9805 in vivo | RMC-9805 in vitro | RMC-9805 formula | RMC-9805 molecular weight